NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90 CHF | +0.99% |
|
+6.48% | +6.04% |
| Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
| Apr. 24 | Novartis Says New Malaria Drug Formulation Safe and Effective for Babies | MT |
ETFs positioned on Novartis AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | - | |
| 5.57% | 18 M€ | +3.04% | - | |
| 4.12% | 88 M€ | +10.37% | - | |
| 3.79% | 2 M€ | -25.75% | ||
| 2.70% | 4 M€ | -.--% | - | |
| 2.55% | 6 M€ | -.--% | ||
| 2.53% | 6 M€ | -.--% | - | |
| 2.00% | 3 M€ | +9.95% | - | |
| 1.50% | 31 M€ | +2.71% | - | |
| 1.44% | 29 M€ | +8.37% | - | |
| 1.43% | 2 M€ | +9.19% | - | |
| 1.43% | 2 M€ | -.--% | - | |
| 1.41% | 182 M€ | +7.15% | ||
| 1.20% | 49 M€ | +4.53% | ||
| 1.15% | 10 M€ | -3.35% | - | |
| 1.00% | 7 M€ | +1.38% | - | |
| 0.98% | 7 M€ | +0.11% | - | |
| 0.74% | 1,120 M€ | -0.07% | ||
| 0.71% | 5 M€ | -.--% | - | |
| 0.53% | 284 M€ | -.--% |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.51
USD
Average target price
108.2
USD
Spread / Average Target
+11.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.04% | 199B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B | |
| +2.07% | 117B |
- Stock Market
- Equities
- NOVN Stock
- Funds and ETFs Novartis AG
